Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Confidential contracting

- PMLiVE

To brand or not to brand…

Questions to ask if you want to deliver an experience like no other

Is ‘value’ in the eye of the beholder?

The concept of value

- PMLiVE

Novartis claims EU approval for breast cancer drug Kisqali

Firm's CDK4/6 inhibitor can now challenge Pfizer's Ibrance in Europe

- PMLiVE

Intra-Cellular plans schizophrenia filing in 2018

Says lumateperone could provide additional benefits over existing treatments

- PMLiVE

Hugh Cole joins Jounce Therapeutics as chief business officer

He also takes up a head of corporate development role at the US firm

- PMLiVE

PharmaLex appoints Dr Adam King to its regulatory team

Dr Adam King joins the German group as a senior director

UK Life Sciences Strategy - one year on

EMA starts firming up its stance on personalised medicines

But draft guidelines won't be ready much before 2019

- PMLiVE

Ironwood claims FDA OK for former AZ gout drug

Duzallo will be launched in the US before the end of this year

- PMLiVE

European Research Council readies €2bn in science funding

Aims to reward potential breakthrough discoveries

- PMLiVE

Astellas extends phase III programme for Rydapt rival gilteritinib

Japanese group hopes its AML drug will soon compete with Novartis' recently-approved treatment

- PMLiVE

Sanofi Genzyme brings The World Vs MS to Denmark

Firm's Communiqué Award winning campaign launches in another local market

Are rare disease companies naturally more patient-centric?

Intuitively it would make sense for these firms to be more connected with their patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links